praliciguat

Asset

Stimulates soluble guanylate cyclase (sGC) to increase cyclic GMP production.

Stage: Phase 2
Modality: Small molecule
Target: GUCY1A1; 1
Indication: 1
Trial: 1
Developer

Indications

1

Focal segmental glomerulosclerosis
Phase 2, Recruiting, NCT07268638, clinicaltrials.gov, 7 Oct 2026

In the full profile

Targets and what it contains2
Owner and partners1
Trials1
Competitors3
Signals1

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026, 1 source